Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Trial Begins Testing Enhanced Cord Blood Stem Cells

A clinical trial testing transplant grafts derived from umbilical cord blood as an alternative to bone marrow stem cells for people with blood-related cancers is treating its first patient. . . . → Read More: Trial Begins Testing Enhanced Cord Blood Stem Cells

Test of Nasal Skin Cells Found to Detect Lung Cancer

A diagnostic test analyzing the genes in skin cells from nasal passages can detect lung cancer, and the absence of cancer, as accurately as more invasive samples from the airways. . . . → Read More: Test of Nasal Skin Cells Found to Detect Lung Cancer

Nuclear Cancer Therapy Company Launches, Raises $25M

A new company developing cancer therapies combining nuclear radiation and synthetic antibodies is starting up in Hamilton, Ontario. . . . → Read More: Nuclear Cancer Therapy Company Launches, Raises $25M

Tissue Regeneration Start-Up Gains $33M in Early Funds

A new enterprise founded by researchers at Stanford University aims to discover and develop drugs that repair and regenerate tissue from stem cells. . . . → Read More: Tissue Regeneration Start-Up Gains $33M in Early Funds

Skin Health Data Collected by App Offered for Research

A smartphone app collecting images and data about moles on the skin of volunteers is now available to researchers for studies of cancer and other disorders. . . . → Read More: Skin Health Data Collected by App Offered for Research

Cancer Drug Shown to Improve Survival Time in Dogs

A drug to treat a deadly cancer in dogs was shown in a clinical trial to extend the survival time of canine patients by 6 months or more, with potential applications in humans. . . . → Read More: Cancer Drug Shown to Improve Survival Time in Dogs

Biotechs License Solid Tumor Therapy in $2.1B Deal

Biotechnology enterprise Immunomedics Inc. is licensing its enhanced antibody-based treatment for solid tumor cancers to Seattle Genetics, a developer of similar cancer drugs. . . . → Read More: Biotechs License Solid Tumor Therapy in $2.1B Deal

Alliance to Study Brain Tumor Precision Diagnostics

A group of medical centers and companies, mainly in Philadelphia, is beginning a study of genomic profiling to diagnose brain tumors in adults and children. . . . → Read More: Alliance to Study Brain Tumor Precision Diagnostics

Grid Computing Harnessed for Childhood Cancer Research

An international consortium is seeking crowdsourced computing power to screen drug candidates for treating a number of cancers affecting children. . . . → Read More: Grid Computing Harnessed for Childhood Cancer Research

Immunotherapy Biotech Raises $102 Million in IPO

A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering. . . . → Read More: Immunotherapy Biotech Raises $102 Million in IPO